China Meheco Group (600056.SH) subsidiary's mupirocin API approved for marketing
China Meheco Group (600056.SH) announced that recently, Tianfang Pharmaceutical Co., Ltd. ("Tianfang Pharmaceutical"), a wholly-owned subsidiary of the company, received the "Chemical API Marketing Application Approval Notice" for mupirocin issued by the National Medical Products Administration. The drug is mainly used for skin and soft tissue infections caused by Gram-positive cocci, such as primary infections including impetigo, furuncles, and folliculitis, as well as secondary infections of skin conditions such as eczema, dermatitis, ulcers, and trauma.
China Meheco Group (600056.SH) announced that recently, Tianfang Pharmaceutical Co., Ltd. ("Tianfang Pharmaceutical"), a wholly-owned subsidiary of the company, received the "Chemical API Marketing Application Approval Notice" for mupirocin issued by the National Medical Products Administration. The drug is mainly used for skin and soft tissue infections caused by Gram-positive cocci, such as primary infections including impetigo, furuncles, and folliculitis, as well as secondary infections of skin conditions such as eczema, dermatitis, ulcers, and trauma.
Related Articles

Jinan Shengquan Group Share Holding (605589.SH) Chairman proposes share buyback of RMB200 million to RMB400 million.

Xtc New Energy Materials (Xiamen) Co., Ltd. (688778.SH) Chairman proposes share repurchase of RMB50 million to RMB100 million.

SDIC Intelligence Information Technology (300188.SZ) plans to increase capital by RMB200 million in its subsidiary.
Jinan Shengquan Group Share Holding (605589.SH) Chairman proposes share buyback of RMB200 million to RMB400 million.

Xtc New Energy Materials (Xiamen) Co., Ltd. (688778.SH) Chairman proposes share repurchase of RMB50 million to RMB100 million.

SDIC Intelligence Information Technology (300188.SZ) plans to increase capital by RMB200 million in its subsidiary.






